Jan Astermark
11 – 20 of 185
- show: 10
- |
- sort: year (new to old)
Close
Embed this list
<iframe src=" "
width=" "
height=" "
allowtransparency="true"
frameborder="0">
</iframe>
- 2023
-
Mark
Koagulationsfaktor XIII – inte bara ett kongenitalt blödningsproblem
(
- Contribution to journal › Scientific review
-
Mark
Gene Therapy with Etranacogene Dezaparvovec for Hemophilia B
(
- Contribution to journal › Article
-
Mark
Applicability of the European Society of Cardiology Guidelines on the management of acute coronary syndromes to older people with haemophilia A – A modified Delphi consensus by the ADVANCE Working Group
(
- Contribution to journal › Scientific review
-
Mark
No difference in quality of life between persons with severe haemophilia A and B
(
- Contribution to journal › Article
-
Mark
Considerations for shared decision management in previously untreated patients with hemophilia A or B
(
- Contribution to journal › Scientific review
-
Mark
The IgG-degrading enzyme, Imlifidase, restores the therapeutic activity of FVIII in inhibitor-positive hemophilia A mice
(
- Contribution to journal › Article
-
Mark
Real-world prophylactic usage of recombinant factor IX Fc in Sweden : A report from the Swedish National Registry for bleeding disorders
(
- Contribution to journal › Letter
-
Mark
Matching-adjusted indirect comparison of bleeding outcomes in severe haemophilia A : Comparing valoctocogene roxaparvovec gene therapy, emicizumab prophylaxis, and FVIII replacement prophylaxis
(
- Contribution to journal › Article
-
Mark
Impact of timing of prophylaxis commencement, F8 genotype and age on factor consumption and health-related quality of life in patients with severe haemophilia A
(
- Contribution to journal › Article
-
Mark
Recombinant factor IX Fc prophylaxis reduces pain and increases levels of physical activity, with sustained, long-term improvements in patients with hemophilia B : post hoc analysis of phase III trials using patient-reported outcomes
(
- Contribution to journal › Article